Andere Sprachen Regulus Therapeutics Inc.

Aktien

A3DNZ4

US75915K3095

RGLS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.05.2024			% 5 Tage	% 1. Jan.
2,045 ^USD	+1,24 %		+1,74 %	+59,77 %

16.05.	Regulus Therapeutics Inc. gibt die Beförderung von Rekha Garg zum Chief Medical Officer bekannt	CI
09.05.	Regulus Therapeutics Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

APPENDIX A REGULUS THERAPEUTICS INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 15, 2019 APPROVED BY THE STOCKHOLDERS: AUGUST 1, 2019 AMENDED BY THE BOARD OF DIRECTORS: APRIL 20, 2023 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2023 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2024 APPROVED BY THE STOCKHOLDERS: MAY 16, 2024 - Form 8-K	17.05.
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer	16.05.
Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer	16.05.
Regulus: Q1 Earnings Snapshot	09.05.
Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates	09.05.
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	06.05.
Regulus Therapeutics Advances to Cohort 4 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	06.05.
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series	30.04.
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Regulus: Q4 Earnings Snapshot	21.03.
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates	21.03.
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.03.
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP	14.03.
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors	14.03.
Top Midday Gainers	12.03.
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise	12.03.
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	12.03.
Top Premarket Gainers	12.03.
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Regulus Therapeutics Inc.

Aktien

A3DNZ4

US75915K3095

RGLS

Andere Sprachen

Filter